BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 28, 2006
View Archived Issues
Plans for clinical investigation of low-dose cortisol for chronic PTSD
Read More
huC242-DM4 appears safe in phase I study
Read More
Assay predicts response to imatinib in CML patients
Read More
Antiarthritic potential of the novel ADAM inhibitor S-44029 demonstrated in vitro
Read More
NDA filed for Zingo needle-free local anesthetic
Read More
Milk thistle components suppress the growth of colon cancer cells
Read More
Snapshots on novel targets in autosomal dominant polycystic kidney disease
Read More
Codevelopment agreements terminated for HFT-290 and NS-126
Read More
Positive results for Atopiclair in pediatric atopic dermatitis
Read More
Inex clears another hurdle towards spin-out of Tekmira
Read More
A-831 begins phase I for hepatitis C
Read More
Mayne Pharma to acquire remaining worldwide rights to Nipent
Read More
Sanofi-aventis reflects on Q3 achievements
Read More
Promising preliminary clinical results for Aegerion's novel MTP inhibitor
Read More
Myocardial protection from postconditioning may be mediated by adenosine A2B receptors
Read More
New anticancer agents imparted in recent patents
Read More
Recent patent literature reports new therapeutic agents insomnia, anxiety, etc.
Read More
Novel PDE4 inhibitors patented by Boehringer Ingelheim, Ranbaxy
Read More
New antiarthritic compounds discovered according to recent patents
Read More
MKC-1106-PP immunotherapy cleared for phase I study in solid malignancies
Read More
Enrollment complete in phase IIa bipolar disorder trial of MEM-1003
Read More
Positive interim findings for Cethrin in treatment of acute spinal cord injury
Read More
Treatment under way in phase III study of phenoxodiol in ovarian cancer
Read More
Halozyme completes enrollment in study of Enhanze Technology
Read More
Schering AG and Stanford University collaborate on molecular imaging
Read More
Organon and Pfizer discontinue asenapine collaboration
Read More
Further positive findings for AN-152 in gynecological and breast cancers
Read More